ArticleOncogene1999
Mitochondrial DNA determines the cellular response to cancer therapeutic agents.
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 176 citations in OpenAlex.
- Mitochondrial DNA alterations in precision oncology: Emerging roles in diagnostics and therapeutics.Clinics (Sao Paulo, Brazil) · 2025Review
- NARFL deficiency caused mitochondrial dysfunction in lung cancer cells by HIF-1α-DNMT1 axis.Scientific reports · 2023Article
- Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.International journal of molecular sciences · 2022Article
- Mechanisms of RPE senescence and potential role of αB crystallin peptide as a senolytic agent in experimental AMD.Experimental eye research · 2022Article
- Chrysophanol localizes in mitochondria to promote cell death through upregulation of mitochondrial cyclophilin D in HepG2 cells.Chinese herbal medicines · 2021Article
- Stacking Effects on Anthraquinone/DNA Charge-Transfer Electronically Excited States.Molecules (Basel, Switzerland) · 2020Article
- TPP-based mitocans: a potent strategy for anticancer drug design.RSC medicinal chemistry · 2020Review
- Nanotechnology in Modern Photodynamic Therapy of Cancer: A Review of Cellular Resistance Patterns Affecting the Therapeutic Response.Pharmaceutics · 2020Review
- Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma.Scientific reports · 2020Article
- Role of the mitochondrial stress response in human cancer progression.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Differential effects of cisplatin on cybrid cells with varying mitochondrial DNA haplogroups.PeerJ · 2020Article
- Mitochondrial Involvement in Cisplatin Resistance.International journal of molecular sciences · 2019Review
- Pharmacology of ME-344, a novel cytotoxic isoflavone.Advances in cancer research · 2019Article
- Single molecule mtDNA fiber FISH for analyzing numtogenesis.Analytical biochemistry · 2018Article
- Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update.International journal of molecular sciences · 2017Review
- Mitochondrial dysfunction and mitochondrial dynamics-The cancer connection.Biochimica et biophysica acta. Bioenergetics · 2017Review
- Photo-activation of the delocalized lipophilic cation D112 potentiates cancer selective ROS production and apoptosis.Cell death & disease · 2017Article
- Distinct radiation responses after in vitro mtDNA depletion are potentially related to oxidative stress.PloS one · 2017Article
- Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?Cancer letters · 2016Review
- Role of mitochondrial dysfunction in cancer progression.Experimental biology and medicine (Maywood, N.J.) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Mutations in the mitochondrial genome leading to mitochondrial dysfunction have been reported in a variety of cancers. However, the potential implication of these findings in the cellular response to cancer therapeutic agents is unclear. To examine the importance of mitochondrial DNA (mitDNA) encoded functions in cancer therapeutic response, we determined the clonogenic survival of HSL2 (Rho+, HeLa subline), and its derivative cell line lacking mitDNA (Rho0) after exposure to different anticancer agents. We found that isogenic Rho0 cells lacking mitDNA were extremely resistant to adriamycin and photodynamic therapy (PDT) induced cell death, whereas the Rho+ cell line was sensitive. However, there was no measurable difference in the responses of these cell lines to either alkylating agent or gamma-radiation. We show that the development of resistance to adriamycin was not due to changes in apoptotic cell death, cell cycle response or to the uptake of adriamycin in isogenic Rho0 cells. We also demonstrate that exposure of HeLa cells to adriamycin leads to mutations in mitDNA. These studies provide direct evidence that mitDNA plays an important role in cellular sensitivity to cancer therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.